Antibody-drug conjugates (ADCs) combine antibody-mediated target recognition with potent cytotoxic payloads to deliver therapeutic agents to specific cells. Their efficacy and safety depend on multiple interrelated factors, including antigen expression, cellular internalization, linker stability, payload release, pharmacokinetics, tumor heterogeneity, and resistance mechanisms. Comprehensive characterization is therefore essential to understand candidate behavior and assess the potential therapeutic window across preclinical development.
This whitepaper examines integrated in vitro and in vivo strategies for ADC characterization, covering binding and internalization, cytotoxicity and bystander killing, serum/plasma stability, pharmacokinetics and pharmacodynamics, efficacy, and safety assessment.
Download this whitepaper to learn:
- How in vitro assays assess ADC binding, internalization, cytotoxicity, bystander effects, and stability
- How integrated in vitro and in vivo studies inform candidate selection, efficacy, pharmacokinetics, and safety
- How developability challenges, resistance mechanisms, and emerging ADC formats shape characterization strategies
